Fatty Acid Biosynthesis Disorders
GlobalData’s reports offer expert analysis, insights and opinions to companies in the world’s largest industries. Explore unique market-leading data today and benefit from access to actionable insight within the Fatty Acid Biosynthesis Disorders market. Reports cover market growth forecasts, trends and research, and more.
Browse our full list of Fatty Acid Biosynthesis Disorders market reports here.
- Currency Conversion is for Indicative purpose only. All orders are processed in US Dollars only.
- USD - US Dollar
- AUD — Australian Dollar
- BRL — Brazilian Real
- CNY — Yuan Renminbi
- EUR — Euro
- GBP — Pound Sterling
- INR — Indian Rupee
- JPY — Japanese Yen
- ZAR — South African Rand
- The Price Conversion is only for the Indicative purpose.
- USD — US Dollar
- AUD — Australian Dollar
- BRL — Brazilian Real
- CNY — Yuan Renminbi
- EUR — Euro
- GBP — Pound Sterling
- INR — Indian Rupee
- JPY — Japanese Yen
- ZAR — South African Rand
-
Product Insights
NewProduct Insights NewFatty Acid Biosynthesis Disorders – Drugs In Development, 2024 Fatty Acid Biosynthesis Disorders – Drugs In Development, 2024
$2,000 | June 2024 Empower your strategies with our Fatty Acid Biosynthesis Disorders – Drugs In Development, 2024 report and make more profitable business decisions. Fatty acid biosynthesis disorders (FABDs) are a group of inherited metabolic disorders that affect the ability of the body to use fatty acids as a source of energy. Fatty acids are long chains of carbon and hydrogen atoms that are stored in fat cells and can be broken down to produce energy when glucose (sugar) is not available. However, people...
-
Product Insights
NewProduct Insights NewSandhoff Disease (Jatzkewitz-Pilz Syndrome) – Drugs In Development, 2024 Sandhoff Disease (Jatzkewitz-Pilz Syndrome) – Drugs In Development, 2024
$2,000 | June 2024 Empower your strategies with our Sandhoff Disease (Jatzkewitz-Pilz Syndrome) – Drugs In Development, 2024 report and make more profitable business decisions. Sandhoff disease is an inherited lipid storage disorder that progressively destroys nerve cells (neurons) in the brain and spinal cord. It is caused by a deficiency of the enzyme beta-hexosaminidase. Symptoms include progressive nervous system deterioration, problems initiating and controlling muscles and movement, increased startle reaction to sound, early blindness, seizures, spasticity, and myoclonus. Treatment includes anticonvulsants to control seizures....
-
Product Insights
NewProduct Insights NewAdrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) – Drugs In Development, 2024 Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) – Drugs In Development, 2024
$2,000 | June 2024 Empower your strategies with our Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) – Drugs In Development, 2024 report and make more profitable business decisions. Adrenoleukodystrophy is a disorder that occurs most often in males. It mainly affects the nervous system and the adrenal glands, which are small glands located on top of each kidney. Abetalipoproteinemia is also a kind of adrenoleukodystrophy (adrenomyeloneuropathy/Schilder-Addison complex). Bassen-Kornzweig syndrome is a rare disease passed down through families in which a person is unable to fully absorb dietary fats...
-
Product Insights
NewProduct Insights NewAdrenomyeloneuropathy (AMN) – Drugs In Development, 2024 Adrenomyeloneuropathy (AMN) – Drugs In Development, 2024
$2,000 | June 2024 Empower your strategies with our Adrenomyeloneuropathy (AMN) – Drugs In Development, 2024 report and make more profitable business decisions. Adrenomyeloneuropathy (AMN) is an inherited condition that affects the spinal cord. It is a form of X-linked adrenoleukodystrophy. On average, people with AMN begin to develop features in the late twenties. Signs and symptoms may include progressive stiffness and weakness of the legs; ataxia; speech difficulties; adrenal insufficiency; sexual dysfunction; and bladder control issues The Adrenomyeloneuropathy (AMN) drugs in development market research...
-
Product Insights
Product Insights Adrenoleukodystrophy) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update Adrenoleukodystrophy) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
$2,500 | June 2023 Adrenoleukodystrophy Clinical Trials Analysis Overview The Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) clinical trial market research report provides an overview of the Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) Clinical trials scenario. This report provides top-line data relating to the clinical trials on Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) and includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report also offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.